This partnership will incorporate the routine use of both the MetaPanel™ and another test, MetaXplore™, into clinical protocols, facilitating joint clinical research to evaluate the impact of these tests on patient outcomes.

Microba Life Sciences Limited has announced promising results from two independent clinical studies, revealing that its MetaPanel™ test can identify gastrointestinal pathogens in over 35% of patients with Inflammatory Bowel Disease (IBD) who are experiencing a flare.

Notably, more than 60% of these pathogens are typically missed by current testing methods, highlighting a significant gap in existing diagnostic capabilities.

The ability to detect these overlooked pathogens, as emphasized by Associate Professor Radford-Smith, could revolutionize IBD treatment by reducing unnecessary therapy escalation and surgical interventions.

The collaboration aims to improve diagnosis and treatment decisions, leveraging Microba's precision diagnostics to establish a next-generation gastroenterology care model.

Microba Life Sciences is committed to improving human health through microbiome research, focusing on developing innovative therapeutics and testing services for chronic diseases.

In a strategic move, Microba has partnered with the Colonoscopy Clinic and Integrated Gut Health to integrate microbial diagnostic testing into routine gastroenterology care, aiming to enhance patient outcomes for over 10,000 patients seen annually by the clinic.

The findings from the studies, led by Associate Professors Jake Begun and Graham Radford-Smith, are expected to be published in peer-reviewed journals, further underscoring the clinical utility of the MetaPanel™ in managing IBD.

With over 7 million people affected by IBD worldwide, Microba's clinically validated MetaPanel™ presents a valuable opportunity to enhance disease management and promote the adoption of advanced testing methods in gastroenterology.

Associate Professor Dan Worthley from the Colonoscopy Clinic has noted the growing demand for precise diagnostic tools to manage chronic gastrointestinal conditions, indicating that Microba's testing offers deeper insights into hidden pathogens and microbiome function.